A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh discovery effort
As Vertex began zeroing in on launching its big combo for cystic fibrosis, the oft-lauded biotech started to selectively snap up new technologies that promised to break the therapeutic mold on the way some diseases are treated.
There was the Semma buyout, looking for a cure for diabetes. There was a deal with CRISPR Therapeutics that just produced some landmark data on curing sickle cell disease. They bought Exonics, with a gene editing approach to curing Duchenne muscular dystrophy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.